Epigenetic determinants of ovarian clear cell carcinoma biology

International Journal of Cancer

Volumn 135, Issue 3, 2014, Pages 585-597

  Yamaguchi, Ken ^a   Huang, Zhiqing ^a   Matsumura, Noriomi ^b   Mandai, Masaki ^c   Okamoto, Takako ^a   Baba, Tsukasa ^b   Konishi, Ikuo ^b   Berchuck, Andrew ^a   Murphy, Susan K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Epigenetic characterization; ERalpha; HNF1; Methylation; Ovarian clear cell carcinoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ESTROGEN RECEPTOR ALPHA; HEPATOCYTE NUCLEAR FACTOR 1;

ARTICLE; BINDING SITE; CARCINOGENESIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE REPRESSION; GENETIC REGULATION; GENETIC TRANSCRIPTION; GENOME; HISTOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; STRESS; VALIDATION STUDY;

EPIGENETIC CHARACTERIZATION; ERALPHA; HNF1; METHYLATION; OVARIAN CLEAR CELL CARCINOMA;

ADENOCARCINOMA, CLEAR CELL; DNA METHYLATION; EPIGENOMICS; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 84901024841     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28701     Document Type: Article

References (51)

1. Barton CA, Hacker NF, Clark SJ, et al. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008; 109: 129-39.
2. Gomez-Raposo C, Mendiola M, Barriuso J, et al. Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol Oncol 2010; 118: 88-92.
3. Cho KR, Shih Ie M,. Ovarian cancer. Annu Rev Pathol 2009; 4: 287-313.
4. Mandai M, Yamaguchi K, Matsumura N, et al. Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol 2009; 14: 383-91.
5. Skirnisdottir I, Seidal T, Karlsson MG, et al. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int J Oncol 2005; 26: 177-83.
6. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-9.
7. Itamochi H, Kigawa J, Terakawa N,. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008; 99: 653-8.
8. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types?. A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008; 109: 370-6.
9. Ricciardelli C, Oehler MK,. Diverse molecular pathways in ovarian cancer and their clinical significance. Maturitas 2009; 62: 270-5.
10. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-43.
11. Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-31.
12. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003; 163: 2503-12.
13. Yamaguchi K, Mandai M, Oura T, et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010; 29: 1741-52.
14. Houshdaran S, Hawley S, Palmer C, et al. DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS One 2010; 5: e9359.
15. Gargiulo G, Minucci S,. Epigenomic profiling of cancer cells. Int J Biochem Cell Biol 2009; 41: 127-35.
16. Asadollahi R, Hyde CA, Zhong XY,. Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol Oncol 2010; 118: 81-7.
17. Wei SH, Balch C, Paik HH, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 2006; 12: 2788-94.
18. Kamalakaran S, Kendall J, Zhao X, et al. Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation. Nucleic Acids Res 2009; 37: e89.
19. Wei SH, Chen CM, Strathdee G, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002; 8: 2246-52.
20. Ahluwalia A, Yan P, Hurteau JA, et al. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol 2001; 82: 261-8.
21. Terasawa K, Toyota M, Sagae S, et al. Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines. Br J Cancer 2006; 94: 914-21.
22. Maeda T, Tashiro H, Katabuchi H, et al. Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability. Br J Cancer 2005; 93: 116-23.
23. Maines-Bandiera SL, Kruk PA, Auersperg N,. Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am J Obstet Gynecol 1992; 167: 729-35.
24. Auersperg N, Maines-Bandiera SL, Dyck HG, et al. Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest 1994; 71: 510-18.
25. Seiler M, Huang CC, Szalma S, et al. ConsensusCluster: a software tool for unsupervised cluster discovery in numerical data. OMICS 2010; 14: 109-13.
26. Matsumura N, Huang Z, Mori S, et al. Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res 2011; 21: 74-82.
27. Johnson WE, Li C, Rabinovic A,. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-27.
28. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-50.
29. Newton MA, Quintana FA, den Boon JA, et al. Random-set methods identify distinct aspects of the enrichment signal in gene-set analysis. Ann Appl Stat 2007; 1: 85-106.
30. Pyeon D, Newton MA, Lambert PF, et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007; 67: 4605-19.
31. Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005; 11: 6116-26.
32. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007; 11: 321-33.
33. Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.
34. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002; 62: 4722-9.
35. Cheung HH, Lee TL, Rennert OM, et al. DNA methylation of cancer genome. Birth Defects Res C Embryo Today 2009; 87: 335-50.
36. Ruike Y, Imanaka Y, Sato F, et al. Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genomics 2010; 11: 137.
37. Kurman RJ, Shih Ie M,. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011; 42: 918-31.
38. Scott M, McCluggage WG,. Current concepts in ovarian epithelial tumorigenesis: correlation between morphological and molecular data. Histol Histopathol 2006; 21: 81-92.
39. Yoon MS, Suh DS, Choi KU, et al. High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array. Oncol Rep 2010; 24: 917-25.
40. Matsumura N, Mandai M, Okamoto T, et al. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci 2010; 101: 2658-63.
41. Pontoglio M,. Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. J Am Soc Nephrol 2000; 11 (Suppl 16): S140-S143.
42. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009; 33: 14-21.
43. Smuc T, Hevir N, Ribic-Pucelj M, et al. Disturbed estrogen and progesterone action in ovarian endometriosis. Mol Cell Endocrinol 2009; 301: 59-64.
44. Fujimura M, Hidaka T, Kataoka K, et al. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol 2001; 25: 667-72.
45. Wiley A, Katsaros D, Chen H, et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006; 107: 299-308.
46. Kaneuchi M, Sasaki M, Tanaka Y, et al. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 2005; 104: 1924-30.
47. Akahane T, Sekizawa A, Okuda T, et al. Disappearance of steroid hormone dependency during malignant transformation of ovarian clear cell cancer. Int J Gynecol Pathol 2005; 24: 369-76.
48. Wright JW, Stouffer RL, Rodland KD,. Estrogen inhibits cell cycle progression and retinoblastoma phosphorylation in rhesus ovarian surface epithelial cell culture. Mol Cell Endocrinol 2003; 208: 1-10.
49. Cunat S, Hoffmann P, Pujol P,. Estrogens and epithelial ovarian cancer. Gynecol Oncol 2004; 94: 25-32.
50. Baylin SB, Jones PA,. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-34.
51. Schetter AJ, Heegaard NH, Harris CC,. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010; 31: 37-49.